Memento mori. История человеческих достижений в борьбе с неизбежным - Эндрю Дойг
Шрифт:
Интервал:
Закладка:
595
J. Cummings et al. Alzheimer’s disease drug development pipeline: 2020, Alzheimer’s and Dementia: Translational Research and Clinical Interventions, 2020, 6. e12050.
596
P. Sebastiani et al. Genetic Signatures of Exceptional Longevity in Humans // PLoS One, 2012, 7.
597
A. D. Roses. Apolipoprotein E affects the rate of Alzheimer’s disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease // Journal of Neuropathology and Experimental Neurology, 1994, 53. P. 429–437.
598
B. J. Morris et al. FOXO3: A Major Gene for Human Longevity — A Mini-Review // Gerontology, 2015, 61. P. 515–525.
599
E. Pennisi. Biologists revel in pinpointing active genes in tissue samples // Science, 2021, 371. P. 1192, 1193.
600
J. L. Platt and M. Cascalho. New and old technologies for organ replacement // Current Opinion in Organ Transplantation, 2013, 18. P. 179–185.
601
M. Cascalho and J. L. Platt. The future of organ replacement: needs, potential applications, and obstacles to application // Transplantation Proceedings, 2006, 38. P. 362–364.
602
L. Xu et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia // New England Journal of Medicine, 2019, 381. P. 1240–1247.
603
K. Musunuru et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates // Nature, 2021, 593. P. 429–434.
604
M. H. Porteus. A New Class of Medicines through DNA Editing // New England Journal of Medicine, 2019, 380. P. 947–959.
605
H. Li et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects // Signal Transduction and Targeted Therapy, 2020, 5. P. 1.
606
C. Sagan. Cosmos. Random House, 1980.
